MYC and small cell lung carcinoma: Strikingly, when the same strategy is applied to small-cell lung cancer (SCLC), on which there has been no significant therapeutic progress since chemotherapy was introduced in the 1970s, SE-associated genes, including MYC family genes, are highly vulnerable to the THZ1 treatment (134).